Universidad Peruana Cayetano Heredia

Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America

Mostrar el registro sencillo del ítem

dc.contributor.author Labarca, Jaime A.
dc.contributor.author Salles, Mauro José Costa
dc.contributor.author Seas Ramos, Carlos Rafael
dc.contributor.author Guzmán-Blanco, Manuel
dc.date.accessioned 2019-02-06T14:51:20Z
dc.date.available 2019-02-06T14:51:20Z
dc.date.issued 2016
dc.identifier.uri https://hdl.handle.net/20.500.12866/5223
dc.description.abstract Increasing prevalence of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii strains in the nosocomial setting in Latin America represents an emerging challenge to public health, as the range of therapeutic agents active against these pathogens becomes increasingly constrained. We review published reports from 2002 to 2013, compiling data from throughout the region on prevalence, mechanisms of resistance and molecular epidemiology of carbapenem-resistant strains of P. aeruginosa and A. baumannii. We find rates of carbapenem resistance up to 66% for P. aeruginosa and as high as 90% for A. baumannii isolates across the different countries of Latin America, with the resistance rate of A. baumannii isolates greater than 50% in many countries. An outbreak of the SPM-1 carbapenemase is a chief cause of resistance in P. aeruginosa strains in Brazil. Elsewhere in Latin America, members of the VIM family are the most important carbapenemases among P. aeruginosa strains. Carbapenem resistance in A. baumannii in Latin America is predominantly due to the oxacillinases OXA-23, OXA-58 and (in Brazil) OXA-143. Susceptibility of P. aeruginosa and A. baumannii to colistin remains high, however, development of resistance has already been detected in some countries. Better epidemiological data are needed to design effective infection control interventions. en_US
dc.language.iso eng
dc.publisher Taylor and Francis
dc.relation.ispartofseries Critical Reviews in Microbiology
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject beta-Lactam Resistance en_US
dc.subject Cross Infection en_US
dc.subject Acinetobacter baumannii/drug effects en_US
dc.subject Acinetobacter Infections/epidemiology/microbiology en_US
dc.subject Anti-Bacterial Agents/pharmacology en_US
dc.subject Carbapenem en_US
dc.subject Carbapenems/pharmacology en_US
dc.subject Humans en_US
dc.subject Incidence en_US
dc.subject infection en_US
dc.subject Latin America en_US
dc.subject Latin America/epidemiology en_US
dc.subject nosocomial en_US
dc.subject Population Surveillance en_US
dc.subject Pseudomonas aeruginosa/drug effects en_US
dc.subject Pseudomonas Infections/epidemiology/microbiology en_US
dc.subject resistance en_US
dc.title Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America en_US
dc.type info:eu-repo/semantics/review
dc.identifier.doi https://doi.org/10.3109/1040841X.2014.940494
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#1.06.01
dc.relation.issn 1549-7828


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas